Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01136772 · ClinicalTrials.gov registry record · Phase 4
A Comparison of Long-acting Injectable Medications for Schizophrenia
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 311
- Enrollment target
NCT01136772 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 311 participants.
The verdict
NCT01136772, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 311 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs).
Interventions
- DRUG paliperidone palmitate
- DRUG haloperidol decanoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 311 participants |
| Start Date | 2011-03 |
| Est. Completion | 2016-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01136772
The ClinicalTrials.gov registry entry for NCT01136772 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 311 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which paliperidone palmitate is the first listed.
NCT01136772 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01136772 about?
NCT01136772 is a clinical study titled "A Comparison of Long-acting Injectable Medications for Schizophrenia". The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benef...
What is the current status of trial NCT01136772?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 311 participants. The study started on 2011-03. Estimated completion is 2016-07.
What interventions are being tested in trial NCT01136772?
The interventions under investigation include: paliperidone palmitate (DRUG), haloperidol decanoate (DRUG).
Who is sponsoring clinical trial NCT01136772?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.